CorVel Corporation Expands Care Advocacy Program

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

CorVel Corporation (NASDAQ: CRVL), a national provider of risk management solutions, has redesigned the Care Advocacy model by expanding the important role played by nurses in the first 30 days of a claim.

CorVel Corporation notes the change allows for a personal and customized program for the company’s customers and their employees.

Care Advocacy is the secondary nursing engagement in CorVel’s workers’ compensation program, following the Advocacy 24/7 nurse. This approach leverages CorVel’s integrated CareMC EdgeSM platform, which identifies claims involving moderate to severe worker injuries and connects a nurse care advocate within 24 hours of the first report.

Unlike other early intervention programs, CorVel’s Care Advocacy model involves the nurse as a patient advocate for up to 30 days after initial contact. The Care Advocate educates the injured worker on their medical diagnosis, treatment plan, and return-to-work options, and engages them in the care and recovery process as an active participant. The Care Advocate understands the claim process and ensures the worker receives care and treatment quickly and effectively. This patient-centered approach to claims management empowers the injured worker, resulting in increased satisfaction and timely return to work.

“Our newly expanded Care Advocacy program is implemented during the first 30 days of a claim—a critical time frame that sets the tone for the claim direction and ultimate outcome,” said Karen Thomas, Director of Case Management Innovation at CorVel Corporation. “During that time, our Care Advocates focus on what’s most important: the injured worker and their well-being. They are true patient advocates who help injured workers navigate the often-confusing claim process. This personalized service can improve medical outcomes and reduce the length of a claim.”

The Care Advocates also drive open communication with all claim stakeholders. They provide critical information for the claim specialist in real time using CorVel’s proprietary CareMC EdgeSM platform, which identifies potential challenges before they become issues. As a result, CorVel’s customers have seen an average 49% decrease in litigated claims, 53% decrease in total temporary disability (TTD) payments, and 74% decrease in total medical paid.

“We are very proud of our reimagined Care Advocacy program, which places an emphasis on the injured worker,” said Michael Combs, President and CEO at CorVel. “At CorVel, we believe that a patient-centered approach to claims management supported by collaborative care, innovative technology and an integrated platform can proactively address potential claims challenges. This will improve outcomes and reduce costs for customers while increasing satisfaction and care for injured workers.”

The Care Advocacy program is a key component of CorVel’s comprehensive workers’ compensation program and can be tailored to fit the needs of customers.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles